These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Treatment Options for Patients With Heavily Pretreated Relapsed and Refractory Multiple Myeloma. Dimopoulos MA; Richardson P; Lonial S Clin Lymphoma Myeloma Leuk; 2022 Jul; 22(7):460-473. PubMed ID: 35148975 [TBL] [Abstract][Full Text] [Related]
4. Multiple myeloma treatment at relapse after autologous stem cell transplantation: A practical analysis. Malard F; Harousseau JL; Mohty M Cancer Treat Rev; 2017 Jan; 52():41-47. PubMed ID: 27888768 [TBL] [Abstract][Full Text] [Related]
5. Sequencing of nontransplant treatments in multiple myeloma patients with active disease. Yee AJ; Raje NS Hematology Am Soc Hematol Educ Program; 2016 Dec; 2016(1):495-503. PubMed ID: 27913521 [TBL] [Abstract][Full Text] [Related]
6. Practical Approaches to the Management of Dual Refractory Multiple Myeloma. Lee HC; Mark TM; Shah JJ Curr Hematol Malig Rep; 2016 Apr; 11(2):148-55. PubMed ID: 26898556 [TBL] [Abstract][Full Text] [Related]
7. Current and New Therapeutic Strategies for Relapsed and Refractory Multiple Myeloma: An Update. Nijhof IS; van de Donk NWCJ; Zweegman S; Lokhorst HM Drugs; 2018 Jan; 78(1):19-37. PubMed ID: 29188449 [TBL] [Abstract][Full Text] [Related]
8. How I treat first relapse of myeloma. Harousseau JL; Attal M Blood; 2017 Aug; 130(8):963-973. PubMed ID: 28679737 [TBL] [Abstract][Full Text] [Related]
9. How have evolutions in strategies for the treatment of relapsed/refractory multiple myeloma translated into improved outcomes for patients? Sonneveld P; De Wit E; Moreau P Crit Rev Oncol Hematol; 2017 Apr; 112():153-170. PubMed ID: 28325256 [TBL] [Abstract][Full Text] [Related]
10. New generation drugs for treatment of multiple myeloma. Alanazi F; Kwa FAA; Burchall G; Jackson DE Drug Discov Today; 2020 Feb; 25(2):367-379. PubMed ID: 31765717 [TBL] [Abstract][Full Text] [Related]
11. Optimizing Immunomodulatory Drug With Proteasome Inhibitor Combinations in Newly Diagnosed Multiple Myeloma. Ntanasis-Stathopoulos I; Terpos E; Dimopoulos MA Cancer J; 2019; 25(1):2-10. PubMed ID: 30694854 [TBL] [Abstract][Full Text] [Related]
12. [Management of multiple myeloma in the relapsed/refractory patient]. Tabayashi T Rinsho Ketsueki; 2019; 60(9):1257-1264. PubMed ID: 31597851 [TBL] [Abstract][Full Text] [Related]
13. Emerging therapies in multiple myeloma. El-Amm J; Tabbara IA Am J Clin Oncol; 2015 Jun; 38(3):315-21. PubMed ID: 23934133 [TBL] [Abstract][Full Text] [Related]
14. [Treatment algorithms for multiple myeloma in Japan]. Ozaki S Rinsho Ketsueki; 2017; 58(8):1014-1023. PubMed ID: 28883264 [TBL] [Abstract][Full Text] [Related]
15. Progress and Paradigms in Multiple Myeloma. Anderson KC Clin Cancer Res; 2016 Nov; 22(22):5419-5427. PubMed ID: 28151709 [TBL] [Abstract][Full Text] [Related]
16. [Therapeutic approach for relapsed/refractory multiple myeloma: the logic and practice]. Kuroda J Rinsho Ketsueki; 2017; 58(10):2058-2066. PubMed ID: 28978849 [TBL] [Abstract][Full Text] [Related]
17. Pooled analysis of the reports of carfilzomib/ixazomib combinations for relapsed/refractory multiple myeloma. Xu W; Sun X; Wang B; Guo H Ann Hematol; 2018 Feb; 97(2):299-307. PubMed ID: 29159498 [TBL] [Abstract][Full Text] [Related]
18. How is patient care for multiple myeloma advancing? Genadieva Stavric S; Bonello F; Bringhen S; Boccadoro M; Larocca A Expert Rev Hematol; 2017 Jun; 10(6):551-561. PubMed ID: 28504554 [TBL] [Abstract][Full Text] [Related]
19. Monoclonal Antibody Therapies in Multiple Myeloma: A Challenge to Develop Novel Targets. Nishida H; Yamada T J Oncol; 2019; 2019():6084012. PubMed ID: 31781214 [TBL] [Abstract][Full Text] [Related]
20. The future of therapy for relapsed/refractory multiple myeloma: emerging agents and novel treatment strategies. Moreau P Semin Hematol; 2012 Jul; 49 Suppl 1():S33-46. PubMed ID: 22727391 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]